ClinicalTrials.Veeva

Menu
F

Fortis Memorial Research Institute | Gurgaon, India

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Etrasimod
Ozanimod
Pomalidomide
ABX464
Bortezomib
Dexamethasone
Teclistamab
Eculizumab
Ibrutinib
PVd

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 15 total trials

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Active, not recruiting
Crohn Disease
Other: Placebo
Drug: Ozanimod

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Enrolling
Myelofibrosis
Drug: Imetelstat
Drug: Best Available Therapy (BAT)

The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) w...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Elotuzumab
Drug: Bortezomib

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd.

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting
Ulcerative Colitis
Drug: Etrasimod

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.

Active, not recruiting
Crohn Disease
Drug: Ozanimod

Trial sponsors

A
A
Celgene logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo
Fresenius Kabi logo
G
G
Johnson & Johnson (J&J) logo
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems